OOIR: Observatory of International Research

Papers

(The TQCC of Gastric Cancer is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)	373
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial	90
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors	82
Apatinib induced ferroptosis by lipid peroxidation in gastric cancer	79
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial	76
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab	66
A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010)	61
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy	56
Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer	48
Artificial intelligence-based diagnosis of upper gastrointestinal subepithelial lesions on endoscopic ultrasonography images	43
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07	42
Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models	38
Landscape of EBV-positive gastric cancer	37
Deep learning system for lymph node quantification and metastatic cancer identification from whole-slide pathology images	36
Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling	35
Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial	35
Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort	35
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer	34
Optimized PD-L1 scoring of gastric cancer	31
Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer	29
A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics	29
Hospital volume following major surgery for gastric cancer determines in-hospital mortality rate and failure to rescue: a nation-wide study based on German billing data (2009–2017)	28
Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based	27
Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways	26
Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance	26

CAF promotes chemoresistance through NRP2 in gastric cancer	25
Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study	25
Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia	24
Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma	24
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma	24
Safe implementation of robotic gastrectomy for gastric cancer under the requirements for universal health insurance coverage: a retrospective cohort study using a nationwide registry database in Japan	23
Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy	23
Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis	23
Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer	23
Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective	23
Association of surgeon and hospital volume with postoperative mortality after total gastrectomy for gastric cancer: data from 71,307 Japanese patients collected from a nationwide web-based data entry	22
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial	21
Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study	21
Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis	21
Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK14	21
EPRS/GluRS promotes gastric cancer development via WNT/GSK-3β/β-catenin signaling pathway	20
Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis	20
Comparison between endoscopic submucosal resection and surgery for the curative resection of undifferentiated-type early gastric cancer within expanded indications: a nationwide multi-center study	20
Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma	20
Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer	19
A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013)	19
Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry	19
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer	19
Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma	19
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)	19
A novel combination of serum microRNAs for the detection of early gastric cancer	19
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers	19
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast	19
Characteristic endoscopic findings of gastric adenocarcinoma of fundic-gland mucosa type	19
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?	19
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit	18
EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein–Barr virus-associated gastric cancer	18
Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression	18
Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study	17
LRRC8A influences the growth of gastric cancer cells via the p53 signaling pathway	16
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab	16
Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations	16
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer	16
ADAMTS10 inhibits aggressiveness via JAK/STAT/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer	15
Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy	15
Robotic gastrectomy for gastric cancer: systematic review and future directions	15
Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells	15
LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway	15
SHARPIN stabilizes β-catenin through a linear ubiquitination-independent manner to support gastric tumorigenesis	15
Integrin β1 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells	15
Nationwide cohort study: cholesterol level is inversely related with the risk of gastric cancer among postmenopausal women	15
CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6	15
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial	14
Histological diversity and molecular characteristics in gastric cancer: relation of cancer stem cell-related molecules and receptor tyrosine kinase molecules to mixed histological type and more histol	14
Insulin and the insulin receptor collaborate to promote human gastric cancer	14

The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration	14
A multi-mode Wnt- and stemness-regulatory module dictated by FOXM1 and ASPM isoform I in gastric cancer	14
SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence	13
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials	13
Performance evaluation of four prediction models for risk stratification in gastric cancer screening among a high-risk population in China	13
Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression	13
Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial	12
The clinical impact of frailty on the postoperative outcomes of patients undergoing gastrectomy for gastric cancer: a propensity-score matched database study	12
Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT)	12
Gastric equivalent of the ‘Holy Plane’ to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson’s historic schema	12
miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer	12
Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study	12
Treatment response after palliative radiotherapy for bleeding gastric cancer: a multicenter prospective observational study (JROSG 17-3)	12
IL-17A promotes Helicobacter pylori-induced gastric carcinogenesis via interactions with IL-17RC	12
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world	12
Clinical advantage of standardized robotic total gastrectomy for gastric cancer: a single-center retrospective cohort study using propensity-score matching analysis	12
Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation	12
Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601	12
Trends in clinical outcomes and long-term survival after robotic gastrectomy for gastric cancer: a single high-volume center experience of consecutive 2000 patients	11
Personalized therapeutic strategies in HER2-driven gastric cancer	11
Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE	11
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?	11
Adequate period of surveillance in each stage for curatively resected gastric cancer: analyzing the time and rates of recurrence	11
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study	11
Direct prediction of genetic aberrations from pathology images in gastric cancer with swarm learning	11
The expression of the alpha1 subunit of Na+/K+-ATPase is related to tumor development and clinical outcomes in gastric cancer	11
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis	11
Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study	11
Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction	10
International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study	10
CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma	10
Development and evaluation of a double-check support system using artificial intelligence in endoscopic screening for gastric cancer	10
Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab	10
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences	10
Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer	10
LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA	10
Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study	10
Cooperation between artificial intelligence and endoscopists for diagnosing invasion depth of early gastric cancer	10
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy w	10
Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study	10